Stoke Therapeutics, Inc. (NASDAQ: STOK) is a Healthcare company (Biotechnology) with a market capitalization of $1.7B. The Maz Rating grades it against the other companies in its sector.
Stoke Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $26.41, Stoke Therapeutics, Inc. trades at 61.1x sales and 5.1x book value. Over the last twelve months it generated about $28M of revenue and a net loss of $248M. It runs a gross margin of 88.5%, an operating margin of -913.1% and a net margin of -862.1%. It shows return on equity of -67.3%, return on invested capital of -72.0% and a free cash flow yield of -12.5%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.24. Over the past 52 weeks the share price ranged from $22.05 to $40.22, with a beta of 1.38.
Stoke Therapeutics, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 13 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Stoke Therapeutics, Inc. (STOK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 19.5% / 30% · Interest income / Revenue 32.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 17.4% / 33% · Receivables / Mkt Cap (36m) 0.55% / 49% · Interest income / Revenue 32.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 17.4% / 33.33% · Receivables / Mkt Cap (24m) 0.55% / 33.33% · Interest income / Revenue 32.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.26% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 74.6% / 33.33% · Receivables / Avg Assets (4Q) 1.98% / 33.33% · Interest income / Revenue 32.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 78.5% / 33.33% · (Cash+Recv) / Total Assets 81.0% / 33.33% · Interest income / Revenue 32.6% / 5% | Fail |
No. As of September 2026, Stoke Therapeutics, Inc. (STOK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Stoke Therapeutics, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 32.6% of each dividend: Stoke Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.